Reorganization Form 8 K

On October 11, 2024, the Board of Directors (the "Board") of Molecular Templates, Inc. (the "Company") unanimously approved, subject to stockholder approval, the liquidation and wind up of the Company through a dissolution pursuant to a plan of distribution while continuing to pursue strategic alternatives and potential funding sources intended to maximize the value of its business and assets. The Company intends to call a special meeting of its stockholders to seek approval of a plan of distribution and will file proxy materials relating to the special meeting with the Securities and Exchange Commission (the "SEC") as soon as practicable. As previously reported, the Company commenced a process to explore strategic alternatives with its third-party advisors more than a year ago. To date, no viable strategic alternatives are available to the Company. Absent a change in circumstances, the Company does not presently expect that its stockholders will receive value for their shares of common stock in connection with a dissolution. If, following stockholder approval of a dissolution, the Board elects to continue to pursue strategic alternatives, complete a funding transaction prior to a dissolution or otherwise determines that the dissolution is not in the Company's best interests or not in the best interests of its stockholders, the Board may direct that the dissolution and/or plan of distribution be abandoned, amended or modified to the extent permitted by Delaware law without the necessity of further stockholder approval. The Company has engaged third-party advisors, Rock Creek Advisors, LLC, to assist the Company in its ongoing efforts to identify strategic alternatives in an effort to monetize and maximize the value of the Company's assets. There can be no assurance that these efforts will yield the desired outcome or result in any distribution to the Company's stockholders.

The Company also plans to wind down the Phase 1 clinical studies for MT-6402and MT-8421but to continue discussions with the U.S. Food and Drug Administration (the "FDA") with respect to MT-0169for autoimmune indications.

On October 11, 2024, the Board approved a reduction in force of substantially all of the Company's employees, other than key members of management necessary to implement the wind up and support the efforts to maximize the value of the business and its assets. The Company estimates that it will incur a negligible amount of costs in connection with the reduction in force, primarily consisting of legal fees and other related termination costs. The Company may incur additional costs as it finalizes all of the actions to be taken. The Company expects that the implementation of the reduction in force will be substantially complete in October 2024.

Forward-Looking Statements

This Form 8-K containsforward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). The Company disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, prospects, plans, objectives of management and future operations are forward-looking statements. In addition, when or if used in this Form 8-K,the words "pursue," "potential," "desired," "seek," "will," "estimate," "expect," "intend," "plan," "may" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Examples of such statements include, but are not limited to, the expectations regarding the estimated costs in connection with the reduction in force, the timing of such costs; and the timing of completion of the reduction in force, the ongoing development of the Company's product candidate MT-0169and related discussions with the FDA, the Company's ability to seek and obtain approval for a dissolution from its stockholders, the potential dissolution itself, potential dissolutions or stockholders(or lack thereof) and any potential strategic or other funding transactions of which there can be no assurance that such potential transactions will occur at all, will occur in the time necessary prior to a dissolution or will be on terms favorable to the Company and its stockholders. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to those risks identified under the heading "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Qfor the quarter ended June 30, 2024 as filed with the SEC on August 14, 2024 and subsequently filed reports. Any forward-looking statements contained in this Form 8-K speakonly as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.